43 results on '"Cho, Eun Kyung"'
Search Results
2. Odd coloring of sparse graphs and planar graphs
3. Independent Domination Versus Packing in Subcubic Graphs
4. Independent domination of graphs with bounded maximum degree
5. Improvements on Hippchen's conjecture
6. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
7. Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
8. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
9. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
10. On induced saturation for paths
11. Partitioning planar graphs without 4-cycles and 5-cycles into bounded degree forests
12. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
13. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
14. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
15. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
16. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
17. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
18. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
19. MA07.07 Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study
20. P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70
21. P3.02b-053 A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data
22. P2.03a-037 Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
23. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
24. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy
25. Pseudopathologic vertebral body enhancement in the presence of superior vena cava obstruction on computed tomography
26. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
27. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
28. Comparison of Characteristics of Bacterial Bloodstream Infection between Adult Patients with Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
29. Impaired endothelial function in medical personnel working sequential night shifts
30. Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer
31. Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia
32. 2,3,7,8-TCDD neurotoxicity in neuroblastoma cells is caused by increased oxidative stress, intracellular calcium levels, and tau phosphorylation
33. A red algal cyclophilin has an effect on development and growth in Nicotiana tabacum
34. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer
35. A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors
36. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation
37. Prospective Pilot Study of Consolidation Chemotherapy With Docetaxel and Cisplatin After Concurrent Chemoradiotherapy for Advanced Head and Neck Cancer
38. P3-129: Second–line therapy with irinotecan or gefitinib in pretreated patients with non–small cell lung cancer: final results of a new treatment strategy according to clinical predictors for response
39. P1-207: Concurrent chemoradiotherapy with irinotecan/cisplatin followed by consolidation chemotherapy with irinotecan/cisplatin in patients with limited-disease small cell lung cancer
40. P1-226: Irinotecan plus carboplatin for patients with extensive-disease small cell lung cancer
41. P3-128: Correlation of the epidermal growth factor receptor mutations with clinical outcomes in patients with non–small cell lung cancer treated gefitinib: an exploratory molecular analysis of a prospective phase II study
42. P2-297: Phase II trial of weekly docetaxel and gemcitabine for chemotherapy-naive patients with advanced non-small cell lung cancer
43. Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.